Senti Biosciences (NASDAQ:SNTI) Stock Price Expected to Rise, Chardan Capital Analyst Says

Senti Biosciences (NASDAQ:SNTI) had its price target lifted by analysts at Chardan Capital from $12.00 to $13.00 in a research note issued on Tuesday,Benzinga reports. The brokerage currently has a “buy” rating on the stock.

Other analysts have also issued research reports about the stock. Leerink Partners initiated coverage on shares of Senti Biosciences in a research note on Friday, November 21st. They set an “outperform” rating and a $6.00 price objective on the stock. Wall Street Zen lowered shares of Senti Biosciences from a “hold” rating to a “sell” rating in a report on Saturday, November 8th. HC Wainwright assumed coverage on shares of Senti Biosciences in a report on Tuesday, October 14th. They issued a “buy” rating and a $12.00 price objective on the stock. Leerink Partnrs upgraded Senti Biosciences to a “strong-buy” rating in a research note on Friday, November 21st. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Senti Biosciences in a research report on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $9.00.

Senti Biosciences Price Performance

Shares of NASDAQ SNTI opened at $1.49 on Tuesday. Senti Biosciences has a 1-year low of $1.26 and a 1-year high of $5.96. The company has a market capitalization of $39.17 million, a price-to-earnings ratio of -0.45 and a beta of 2.08. The business has a 50-day moving average of $1.95 and a 200-day moving average of $1.97.

Senti Biosciences (NASDAQ:SNTI) last announced its earnings results on Thursday, November 13th. The company reported ($0.69) EPS for the quarter, missing the consensus estimate of ($0.59) by ($0.10). Research analysts expect that Senti Biosciences will post -14.54 EPS for the current fiscal year.

Institutional Investors Weigh In On Senti Biosciences

A number of institutional investors have recently modified their holdings of the stock. Armistice Capital LLC bought a new position in shares of Senti Biosciences during the second quarter worth about $1,883,000. Nantahala Capital Management LLC acquired a new stake in Senti Biosciences during the first quarter valued at approximately $2,984,000. Heights Capital Management Inc. bought a new position in Senti Biosciences during the 1st quarter worth approximately $2,520,000. Geode Capital Management LLC grew its position in shares of Senti Biosciences by 395.6% in the 2nd quarter. Geode Capital Management LLC now owns 147,314 shares of the company’s stock worth $311,000 after acquiring an additional 117,588 shares in the last quarter. Finally, Citadel Advisors LLC bought a new stake in shares of Senti Biosciences in the 3rd quarter valued at approximately $117,000. Institutional investors and hedge funds own 25.70% of the company’s stock.

Senti Biosciences Company Profile

Senti Biosciences, Inc operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications.